1. Chen L-M. UpToDate: UpToDate in Waltham, MA; 2023.
2. DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2008.
3. Batra S, Iosif CS. Elevated concentrations of antiestrogen binding sites in membrane fractions of human ovarian tumors. Gynecol Oncol. 1996;60(2):228–32.
4. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002;8(7):2233–9.
5. Chan KKL, Ngu SF, Chu MMY, Tse KY, Ngan HYS. Tamoxifen use in recurrent ovarian cancer in a Chinese population: a 15-year clinical experience in a tertiary referral center. Asia Pac J Clin Oncol. 2021;17(4):338–42.